Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.13 USD
-0.02 (-1.74%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $1.15 +0.02 (1.77%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Clearside Biomedical, Inc. [CLSD]
Reports for Purchase
Showing records 221 - 240 ( 274 total )
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
ME-NIU NDA Submitted; We Anticipate FDA Acceptance of Filing in Q1
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Next: NDA Submission for ME-NIU by YE:18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
NDA Submission on Track for ME-NIU by YE; Reiterate OP but Reducing PT to $4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
AAO Data Highlights XIPERE ?s Differentiated Clinical Profile in Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Attractive Value in Front of Multiple Near-Term Potential Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Top-Line RVO Data for Phase 3 SAPPHIRE Trial Remains On- Track for Q4:18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Exploratory DME Phase 2 Hits Non-inferiority; Anticipate Next Steps in 2018
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Exploratory DME Phase 2 Hits Non-inferiority; Anticipate Next Steps in 2018
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Clearside Biomedical, Inc.
Industry: Unclassified
HULK versus TYBEE for DME: We See Near-Term Upside from Phase 2 Results
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Week Ahead
Provider: WEDBUSH SECURITIES INC.
Company: Clearside Biomedical, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Q1 Financials and First NDA Submission for CLS-TA in Q4:18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Suprachoroidal CLS-TA to Advance on Multiple Fronts in 2018
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L